Global Pernicious Anemia Market Research and Forecast, 2022-2028

Global Pernicious Anemia Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Complete Blood Count Test, Vitamin B-12 Deficiency Test, Biopsy, and Intrinsic Factor Deficiency Test), By Treatment (Vitamin B-12 Injections, Vitamin B-12 Pills and Other), Forecast Period 2021-2027

The global pernicious anemia diagnosis and treatment market is anticipated to grow at a significant CAGR of 7.1% during the forecast period. Pernicious anemia is a disease in which the formation of red blood cells becomes slow due to deficiency of vitamin B-12 in the human body. The prime cause behind the disease is an autoimmune disorder in which the antibody released by the immune system harms the intrinsic factor present in the stomach. The intrinsic factors play a vital role in the absorption of vitamin B-12 from the food. The deficiency of B-12 leads to a shortage of red blood cells in the bloodstream thereby leading to carry less oxygen to the blood. Elderly people are more prone to such diseases. The increasing prevalence of the autoimmune condition or intestinal diseases is the major motivating factor for the growth of the global pernicious anemia market. Moreover, effective medication techniques for treating autoimmune disorders also account for the growth of the market.

The lack of awareness about the treatment of disease and the high cost of the drug is the major factors restraining the growth of the market. The supportive government regulations and increased expenditure for the development of healthcare infrastructure will create more room for future growth of the market. Moreover, the rapid research and development in the field of novel treatment methods will also help in increasing the market across the globe.

Impact of COVID-19 Pandemic on Global Pernicious Anemia Market

Due to the outbreak of COVID-19, all the pharmaceutical industries are focused and rushed towards the research and development of medicine and vaccine for COVID-19. This had sidelined the diagnosis and treatment of other diseases due to the that lots of people are losing their life. Pernicious anemia disease is also experiencing the same challenges. However, as published by National Center for Biotechnology Information (NCBI) that deficiency of vitamin B12 is increasing the fatality of COVID-19. It was also published that a COVID-19 patient who had received a combination of vitamin D, magnesium, and vitamin B12 nutrients are having fewer chances of needing oxygen and intensive care support. So, if the deficiency of vitamin B12 is reduced or pernicious anemia is actively diagnosed and treated in this pandemic then fatality can be reduced.

Segmental Outlook

The global pernicious anemia diagnosis and treatment market is segmented based on diagnosis, and treatment. Based on the material, the market is segmented into complete blood count tests, vitamin B-12 deficiency tests, biopsy, and intrinsic factor deficiency tests. Based on the treatment, the market is segmented into vitamin B-12 injections and vitamin B-12 pills.

Global Pernicious Anemia Diagnosis and Treatment Market Share by Diagnosis, 2020 (%)

Global Pernicious Anemia Diagnosis and Treatment Market Share by Diagnosis

Complete Blood Count Test is the Most Common and Initial Level of Testing Pernicious Anemia

The complete blood count test is the most common test prescribed by the physicians for the initial level of testing. In this test hemoglobin and hematocrit levels are checked to diagnose pernicious anemia in a person. This test is also commonly prescribed for various other diseases due to which sometimes pernicious anemia gets detected. Vitamin B12 deficiency test is also now getting popularized to directly detect this disease as pernicious anemia is caused by deficiency of vitamin B12, so if the level of vitamin B12 is tested lower than the normal level then that indicates the person is diseased with pernicious anemia.

The other biopsy and intrinsic factor (IF) deficiency test is conducted on only severe patients due to that it is not much used. The biopsy test is conducted on the tissue sample of the patient body to know which portion of the patient's body is infected and up to what level and if that portion is tested highly infected than normal level then that portion of the patient's body needs to be separated. IF deficiency test is conducted to know whether the antibodies present in inpatient is attacking its healthy cells or not. If the result is positive then further medical treatment is given to the patient.

Regional Outlooks

The global pernicious anemia diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others, and the Rest of the World (the Middle East and Africa, and Latin America).

Global Pernicious Anemia Diagnosis and Treatment Market Growth, by Region 2021-2027

Global Pernicious Anemia Diagnosis and Treatment Market Growth, by Region

North America can treat Global Pernicious Anemia Disease

North America has a tremendous amount of health facilities for such diseases that keep this region ahead in treating pernicious anemia. According to NCBI, around 15% of the elderly population of the US and Europe are having pernicious anemia due to vitamin B12 deficiency. Europe holds a substantial growth in the pernicious anemia market with the increasing government initiatives and investments. The pernicious anemia market will grow significantly in the Asia-Pacific region during the forecast period with the increasing number of geriatric populations and increasing health awareness amongst people. The pernicious anemia shows unusual symptoms in African people due to that it is difficult to resemble this market in the African region.

Market Players Outlook

The competition in the global pernicious anemia diagnosis and treatment market is moderate as the companies present in the market are not so active. The market players are engaged in providing various B-12 vitamin injections, sprays, immunosuppressant drugs, and tests for Intrinsic factor deficiency. The key players in the pernicious anemia market include American Regent, Inc., Daiichi Sankyo Co, Ltd., Emisphere Technologies, Inc, and so on. The companies are engaged in rapid research and development for the development of effective treatment measures for the disease.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global pernicious anemia diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.